Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Banner Gateway Medical Center — Gilbert, Arizona
- Banner MD Anderson Cancer Center — Gilbert, Arizona
+ 251 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Locations: - Palo Verde Hematology Oncology — Glendale, Arizona
- Mayo Clinic Building - Phoenix — Phoenix, Arizona
- Mayo Clinic Hospital — Phoenix, Arizona
+ 129 more sites in the U.S.
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Locations: - Clinical Study Site — Mobile, Alabama
- Clinical Study Site — Tuscaloosa, Alabama
- Clinical Study Site — Goodyear, Arizona
+ 109 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Banner-University Medical Center Phoenix — Phoenix, Arizona
+ 59 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Locations: - Mayo Clinic - Arizona ( Site 0090) — Phoenix, Arizona
- Orange Coast Memorial Medical Center ( Site 2007) — Fountain Valley, California
- Los Angeles Hematology Oncology Medical Group ( Site 0084) — Los Angeles, California
+ 45 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Locations: - Local Institution - 0428 — Tucson, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Locations: - Ironwood Cancer and Research Centers Scottsdale — Chandler, Arizona
- Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Locations: - City Of Hope - Phoenix /ID# 279450 — Goodyear, Arizona
- Highlands Oncology Group - Springdale /ID# 279444 — Springdale, Arkansas
- City of Hope National Medical Center /ID# 279449 — Duarte, California
+ 15 more sites in the U.S.
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Locations: - Yale University — New Haven, Connecticut
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
+ 6 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of …
Sponsor: Genmab
NCT ID: NCT07702032
Locations: - Genesis Cancer Center — Hot Springs, Arkansas
- Valkyrie Clinical Trials - Los Angeles — Los Angeles, California
- Low Country Cancer Care Associates_Savannah_1 — Savannah, Georgia
+ 4 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial studies how well pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with mitomycin works versus (vs) standard chemotherapy (leucovorin calcium, fluorouracil, and irinotecan hydrochloride \[FOLFIRI regimen\] p…
Sponsor: City of Hope Medical Center
NCT ID: NCT07271355
Locations: - CTCA at Western Regional Medical Center — Goodyear, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
+ 2 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other …
Sponsor: Genmab
NCT ID: NCT07775287
Locations: - Valkyrie Clinical Trials - Los Angeles — Los Angeles, California
- Low Country Cancer Care Associates_Savannah_2 — Savannah, Georgia
- Vista Oncology - West Olympia_Olympia_2 — Olympia, Washington